13F Holdings
中文EN

INDP Indaptus Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1857044 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY20.0%
TTM EPS YoY89.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-180.7%
ROA-70.9%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets66.9%
Debt / equity0.00x
Current ratio—
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.01x
Accruals ratio0.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$9.34M$7.25M$7.62M$6.32M$2.52M
SG&A expense$10.49M$8.11M$8.76M$8.59M$5.21M
Operating income-$19.83M-$15.37M-$16.38M-$14.91M-$7.73M
Pretax income-$20.85M-$15.02M———
Income tax$1,716$1,700$2,450$30$1,650
Net income-$20.85M-$15.02M-$15.42M-$14.32M-$7.71M
EBITDA—-$15.37M-$16.38M-$14.91M-$7.73M
EPS (basic)-21.58-44.96-1.83-1.73-1.89
EPS (diluted)-21.58-44.96-1.83-1.73-1.89
Weighted avg. shares (diluted)966,124334,1338.40M8.26M4.09M
Balance sheet
Cash & equivalents$8.51M$5.79M$13.36M$9.63M$39.13M
Short-term investments———$16.81M—
Current assets$9.31M$6.62M$14.00M$27.24M$40.39M
PP&E, net——$735$2,019$3,800
Total assets$9.31M$7.34M$14.92M$28.06M$40.58M
Current liabilities$6.16M$3.39M$2.77M$3.43M$4.60M
Total liabilities$6.16M$3.39M$2.85M$3.43M$4.68M
Shareholders' equity$3.15M$3.94M$12.08M$24.63M$35.90M
Shares outstanding2.17M428,7998.40M8.40M8.26M
Cash flow statement
Operating cash flow-$14.82M-$12.32M-$13.41M-$13.08M-$11.29M
Capital expenditure————$3,854
Free cash flow————-$11.29M
Investing cash flow——$17.14M-$16.43M$447,746
Financing cash flow$17.54M$4.75M——$48.34M
Depreciation & amortization—$735$1,284$1,781$1,403
Stock-based compensation$1.36M$2.31M$2.97M$2.96M$1.51M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.